[Current advances in immunotherapy in ovarian cancer]

Area of Science:

• Oncology
• Immunology
• Cancer Therapy

Background:

• Ovarian cancers possess immunogenic antigens, leading to immune infiltration that impacts prognosis.
• Immunotherapy is a biologically rational approach for ovarian cancer treatment.
• Current anti-PD-1/PD-L1 immune checkpoint inhibitors (ICPIs) show limited efficacy as monotherapy in heavily pre-treated ovarian cancer patients.

Purpose of the Study:

• To review the current landscape of immunotherapy in ovarian cancer.
• To identify predictive biomarkers for response and resistance to ICPIs.
• To explore effective combination strategies for anti-PD-1 or anti-PD-L1 therapy.

Main Methods:

• Review of Phase I and II clinical trial data for ICPIs in ovarian cancer.
• Evaluation of various combination therapies with ICPIs.
• Assessment of emerging immunotherapeutic approaches, including cell therapies.

Main Results:

• Monotherapy with anti-PD-1/PD-L1 agents has shown limited success in heavily pre-treated patients.
• Combinations of ICPIs with chemotherapy have yielded disappointing results.
• Promising results are emerging from combinations of ICPIs with PARP inhibitors, anti-angiogenic agents, and CTLA-4 inhibitors.

Conclusions:

• Identifying predictive biomarkers is crucial for optimizing ICPI efficacy in ovarian cancer.
• Combination therapies, particularly with PARP inhibitors, anti-angiogenic agents, and CTLA-4 inhibitors, hold significant promise.
• Cell-based immunotherapies represent a potential future direction, though further clinical data is needed.